Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$120,000.00

IntraoPerativE paRathyroid hormonE monitorinG to guide suRgery In reNal hypErparathyroIdism (PEREGRINE): A pilot trial

EF 2024-25

Résumé
Chronic kidney disease (CKD) affects over 800 million people worldwide and is rising in prevalence alongside an aging population and growing rates of obesity. In Canada, costs of managing advanced CKD and its sequelae exceeds $40 billion. Secondary and tertiary hyperparathyroidism [a.k.a. renal hyperparathyroidism (RHPT)] are common complications of CKD and affect up to 80% of patients with CKD. RHPT is associated with worse patient mortality, quality of life, and cognitive function. Parathyroidectomy is often indicated as definitive therapy in RHPT but has failure rates as high as 27%. Intraoperative PTH (IOPTH) monitoring, which permits blood monitoring of PTH levels during surgery, can reduce surgical failure rates by as much as 25% in RHPT, but so far there are no consensus guidelines for its use in RHPT, which underscores the need for a randomized controlled trial (RCT). The PEREGRINE pilot trial is a multi-center, multi-arm, parallel, blinded RCT that aims to assess the feasibility of a full RCT evaluating the role for IOPTH-guided surgery in reducing recurrent hyperparathyroidism in RHPT. Adults with secondary or tertiary hyperparathyroidism will be randomized to undergo parathyroidectomy without IOPTH or with IOPTH using four types of IOPTH monitoring criteria. This trial will enroll 60 patients to assess randomization, surgeon crossover, follow-up completion, blinding effectiveness, and cost to assess the feasibility of a final RCT powered to evaluate the effectiveness of IOPTH monitoring in RHPT. A fully powered RCT that demonstrates a role for IOPTH-guided surgery in RHPT will reduce the risk and economic burden associated with persistent RHPT and revision surgery. It will improve the health of CKD patients living in Canada and will streamline the perioperative costs of surgical care. The use of adaptive trial methodologies in the final trial will also explore the role for these innovative designs in improving and expediting evidence-based surgical care.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
518235
Name
Staibano Phillip
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
IntraoPerativE paRathyroid hormonE monitorinG to guide suRgery In reNal hypErparathyroIdism (PEREGRINE): A pilot trial
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Chronic Kidney Disease; Clinical Trial; Endocrine; Hyperparathyroidism; Parathyroid; Parathyroidectomy; Pilot Trial; Surgery
Abstract
Chronic kidney disease (CKD) affects over 800 million people worldwide and is rising in prevalence alongside an aging population and growing rates of obesity. In Canada, costs of managing advanced CKD and its sequelae exceeds $40 billion. Secondary and tertiary hyperparathyroidism [a.k.a. renal hyperparathyroidism (RHPT)] are common complications of CKD and affect up to 80% of patients with CKD. RHPT is associated with worse patient mortality, quality of life, and cognitive function. Parathyroidectomy is often indicated as definitive therapy in RHPT but has failure rates as high as 27%. Intraoperative PTH (IOPTH) monitoring, which permits blood monitoring of PTH levels during surgery, can reduce surgical failure rates by as much as 25% in RHPT, but so far there are no consensus guidelines for its use in RHPT, which underscores the need for a randomized controlled trial (RCT). The PEREGRINE pilot trial is a multi-center, multi-arm, parallel, blinded RCT that aims to assess the feasibility of a full RCT evaluating the role for IOPTH-guided surgery in reducing recurrent hyperparathyroidism in RHPT. Adults with secondary or tertiary hyperparathyroidism will be randomized to undergo parathyroidectomy without IOPTH or with IOPTH using four types of IOPTH monitoring criteria. This trial will enroll 60 patients to assess randomization, surgeon crossover, follow-up completion, blinding effectiveness, and cost to assess the feasibility of a final RCT powered to evaluate the effectiveness of IOPTH monitoring in RHPT. A fully powered RCT that demonstrates a role for IOPTH-guided surgery in RHPT will reduce the risk and economic burden associated with persistent RHPT and revision surgery. It will improve the health of CKD patients living in Canada and will streamline the perioperative costs of surgical care. The use of adaptive trial methodologies in the final trial will also explore the role for these innovative designs in improving and expediting evidence-based surgical care.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Staibano, Phillip
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~